AZN
AstraZeneca PLC

18,783
Mkt Cap
$194.33B
Volume
2.38M
52W High
$86.57
52W Low
$61.24
PE Ratio
31.03
AZN Fundamentals
Price
$83.29
Prev Close
$83.40
Open
$83.45
50D MA
$80.86
Beta
0.37
Avg. Volume
4.09M
EPS (Annual)
$2.27
P/B
5.78
Rev/Employee
$573,655.92
Loading...
Loading...
News
all
press releases
Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline
Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
Zacks·2d ago
News Placeholder
Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?
Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.
Zacks·3d ago
News Placeholder
AbbVie Up More Than 30% in 6 Months: How to Play the Stock
AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.
Zacks·4d ago
News Placeholder
The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies
Zacks spotlights AstraZeneca, RTX, and Applied Materials for strong performance and growth potential, while microcap names Park Aerospace and NetSol Technologies show niche momentum.
Zacks·6d ago
News Placeholder
Top Research Reports for AstraZeneca, RTX & Applied Materials
AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.
Zacks·6d ago
News Placeholder
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.
Zacks·6d ago
News Placeholder
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·6d ago
News Placeholder
AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer
The Phase 3 trial showed Enhertu achieved a 67.3% complete response rate, outperforming standard therapy by more than 11 percentage points in high-risk HER2-positive early breast cancer.
Stocktwits·7d ago
News Placeholder
DATROWAY (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual...
Business Wire·8d ago

Latest AZN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.